Drugs / belagenpumatucel-L
belagenpumatucel-L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01279798 | — | non-small cell lung carcinoma | NovaRx Corporation | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | belagenpumatucel-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01279798 ↗ |
| Action | Inhibit | “transforming growth factor beta-2 inhibition” PMID 16966690 ↗ Sep 2006 |
| Modality | Vaccine | “Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine” PMID 16966690 ↗ Sep 2006 |
| Target | TGFB2 | “transforming growth factor beta-2 inhibition” PMID 16966690 ↗ Sep 2006 |